Seres Therapeutics, Inc. (MCRB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 33 | 145 | 0 | 0 | 0 | 1 | 2 | - |
| Operating profit | $m | -94 | -84 | ||||||
| Net profit | $m | -89 | -66 | -250 | -114 | -147 | 6 | -22 | -37 |
| EPS reported | $ | 0.64 | -2.41 | ||||||
| Operating cashflow per share | $ | 0.13 | -5.31 | ||||||
| Capex per share | $ | 0.03 | 0.00 | ||||||
| FCF per share | $ | 0.10 | -5.32 | ||||||
| Free cash flow | $m | 1 | -51 | ||||||
| Net debt | $m | -35 | -16 | ||||||
| Book value equity | $m | 44 | 35 | ||||||
| Book value per share | $ | 4.99 | 3.58 | ||||||
| Number of shares | m | 8.87 | 9.64 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 23.25 | - | ||||||
| P/B LTM | x | 2.98 | 3.82 | ||||||
| P/S LTM | x | 167.07 | 70.01 | ||||||
| P/FCF LTM | x | 152.39 | -2.57 | ||||||
| EV/EBITDA LTM | x | 17.20 | -3.81 | ||||||
| EV/Sales LTM | x | 214.22 | 45.15 | ||||||
| Earnings Yield LTM | % | +4.30% | -51.30% | ||||||
| FCF Yield | % | +0.66% | -38.91% | ||||||
| Quality | |||||||||
| ROE | % | +12.88% | -60.32% | ||||||
| ROIC | % | -72.70% | -89.99% | ||||||
| Operating margin | % | -119.10% | -44.63% | ||||||
| Gross margin | % | -4.24% | +82.58% | ||||||
| FCF/Sales | % | +109.63% | -2724.1% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.01 | -0.91 | ||||||
| Net Debt/EBITDA | x | 3.78 | -0.93 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +7.88% | 0.00% | ||||||
| Net debt/Equity | x | -0.80 | -0.45 | ||||||
| Gross debt/equity | x | 1.88 | 1.64 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free